FDA Orange Book · active-ingredient family
Cipepofol
Cipepofol: 1 brand, 0 generics; first approved Aug 27, 2026.
Brand only1 exclusivity period
Generic status & protection
Marketing exclusivity runs through Aug 27, 2031.
Latest exclusivity ends
Brands (NDA)
1
Generics (ANDA)
0
Listed patents
0
Presentations
1
Brand (NDA) products
Originator applications
- HAISCONDA 2204822026
Approved strengths under this FDA application. Strength Dosage form Route Status TE 50MG/20ML (2.5MG/ML) EMULSION INTRAVENOUS Rx —
Patent & exclusivity timeline
Protection horizon
Patent expiryExclusivity endToday
Marketing exclusivity
Hatch-Waxman
- NCENew chemical entity exclusivity (5 years)
in 5 yr
Listed patents
Orange Book patent file
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Approval history
FDA approval span
First approval
26 d ago
Most recent approval
26 d ago
All 1 application were approved in 2026.
Brand (NDA) 1100%
Generic (ANDA) 00%
Cipepofol: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
